2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension

US7314871B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Ulrich Niewohner · Wermelskirchen, DE
• Helmut Haning · Milford, US
• Thomas Schenke · Odenthal, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Jörg Keldenich · Wuppertal, DE
• Erwin Bischoff · Wuppertal, DE
• Elisabeth Perzborn · Wuppertal, DE
• Klaus Dembowsky · Boston, US
• Peter Serno · Bensberg, DE
• Marc Nowakowski · Wuppertal, DE
• Ulrich Niewhner, deceased · Wermelskirchen, DE

Key dates

• Filing date: Apr 21, 2006
• Grant date: Jan 1, 2008
• Expiry date: Apr 21, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application claims a method for treating hypertension by administering an effective amount of a compound of the formula (I)wherein the variable groups are as defined in the specification and claims. These 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.